THE NEXT REVOLUTION
IN CELL THERAPY

Allogene is developing allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapy to find the next immunologic breakthrough in cancer. That’s how we’re leading today, creating tomorrow.

LEARN
ABOUT
AlloCAR T™
THERAPY

LEADING THE FUTURE OF CELL THERAPY
WITH OUR AlloCAR T™ PLATFORM

INNOVATION

Multiplex gene-engineering and gene-editing capabilities
Proprietary lymphodepletion platform
State-of-the-art manufacturing
Opportunity for product optimization

SEE OUR PIONEERING
PLATFORM ››

PIPELINE

Upcoming milestones

- Initial Phase 1 ALLO-715 UNIVERSAL trial data
- File IND for ALLO-316 (anti-CD70 CAR)

EXPLORE OUR
ROBUST PIPELINE ››

LEADERSHIP

A highly experienced management team that includes key pioneers of CAR T cell therapy
200+ employees singularly focused on the development of AlloCAR T™ therapy
Allogene is proud to have approximately 50% of our senior leadership team and entire organization identify as female.

MEET OUR
MANAGEMENT TEAM ››

WE DON’T JUST SEE THE FUTURE.

WE KNOW HOW TO GET THERE.

Allogene is working to overcome the limitations of autologous CAR T immunotherapy by developing AlloCAR T™ therapies. The goal of our allogeneic platform is simple: combine gene-editing technology with cutting-edge cell-therapy manufacturing to deliver the clinical benefits of cell therapy. We start with T cells from healthy donors to allow for the creation of off-the-shelf inventory for the potential to treat all eligible patients faster, more reliably, and at greater scale.